First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses

BACKGROUND: Vaccination with inactivated (killed) whole-virus particles has been used to prevent a wide range of viral diseases. However, for an HIV vaccine this approach has been largely negated due to inherent safety concerns, despite the ability of killed whole-virus vaccines to generate a strong...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Eunsil, Michalski, Chad J., Choo, Seung Ho, Kim, Gyoung Nyoun, Banasikowska, Elizabeth, Lee, Sangkyun, Wu, Kunyu, An, Hwa-Yong, Mills, Anthony, Schneider, Stefan, Bredeek, U. Fritz, Coulston, Daniel R., Ding, Shilei, Finzi, Andrés, Tian, Meijuan, Klein, Katja, Arts, Eric J., Mann, Jamie F. S., Gao, Yong, Kang, C. Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126836/
https://www.ncbi.nlm.nih.gov/pubmed/27894306
http://dx.doi.org/10.1186/s12977-016-0317-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126836/
https://www.ncbi.nlm.nih.gov/pubmed/27894306
http://dx.doi.org/10.1186/s12977-016-0317-2

Ejemplares similares